MA39146A1 - Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma - Google Patents

Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma

Info

Publication number
MA39146A1
MA39146A1 MA39146A MA39146A MA39146A1 MA 39146 A1 MA39146 A1 MA 39146A1 MA 39146 A MA39146 A MA 39146A MA 39146 A MA39146 A MA 39146A MA 39146 A1 MA39146 A1 MA 39146A1
Authority
MA
Morocco
Prior art keywords
gabapentanoids
combinations
receptor ligands
sigma receptor
combination
Prior art date
Application number
MA39146A
Other languages
English (en)
Inventor
Daniel Zamanillo-Castanedo
Enrique Portillo-Salido
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39146(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA39146A1 publication Critical patent/MA39146A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une combinaison synergique comprenant un ligand de sigma représenté par la formule générale (i), et un gabapentanoïde, un médicament comprenant ladite combinaison de substances actives, et l'utilisation de ladite combinaison de substances actives pour la fabrication d'un médicament, en particulier pour la prophylaxie et/ou le traitement de la douleur.
MA39146A 2013-12-17 2014-12-16 Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma MA39146A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382517 2013-12-17
PCT/EP2014/077992 WO2015091505A1 (fr) 2013-12-17 2014-12-16 Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma

Publications (1)

Publication Number Publication Date
MA39146A1 true MA39146A1 (fr) 2017-11-30

Family

ID=49876521

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39146A MA39146A1 (fr) 2013-12-17 2014-12-16 Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma

Country Status (16)

Country Link
US (1) US20160310501A1 (fr)
EP (1) EP3082790A1 (fr)
JP (1) JP2017503765A (fr)
KR (1) KR20160098426A (fr)
CN (1) CN105873580B (fr)
AR (1) AR101637A1 (fr)
AU (1) AU2014364644A1 (fr)
CA (1) CA2933057A1 (fr)
IL (1) IL245977A0 (fr)
MA (1) MA39146A1 (fr)
MX (1) MX2016007286A (fr)
PH (1) PH12016501095A1 (fr)
SG (1) SG11201604478UA (fr)
TN (1) TN2016000229A1 (fr)
TW (1) TW201607539A (fr)
WO (1) WO2015091505A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (fr) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2353591A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
EP2353598A1 (fr) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour utilisation dans la prévention et/ou le traitement de la douleur post-opératoire
EP2388005A1 (fr) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
EP2415471A1 (fr) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
EP2524694A1 (fr) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans la douleur liée au diabète de type 2
TW201607538A (zh) 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
CA3121202A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composes pyrrole et pyrazole et leurs procedes d'utilisation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1992009560A1 (fr) 1990-11-27 1992-06-11 Northwestern University Analogues de l'acide gamma-aminobutyrique (gaba) et de l'acide l-glutamique utilises dans le traitement contre les attaques
SG48288A1 (en) 1992-05-20 1998-04-17 Univ Northwestern Gaba and l-glutamic acid analogs for antiseizure treatment
DK1032555T3 (da) 1997-10-27 2006-07-17 Warner Lambert Co Cykliske aminosyrer og derivater deraf, som er anvendelige som lægemidler
NZ503980A (en) 1997-12-16 2002-09-27 Warner Lambert Co 4(3)substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (= gabapentin analogues), pharmaceuticals thereof, and their use in the treatment of neurological disorders
IL135314A0 (en) 1997-12-16 2001-05-20 Warner Lambert Co Novel amines as pharmaceutical agents
PT1047678E (pt) 1997-12-16 2004-12-31 Warner Lambert Co Derivados do 1-aminometil-cicloalcano substituido em 1 (=analogos da gabapentina) sua preparacao e sua utilizacao no tratamento de disturbios neurologicos
AU757445B2 (en) 1998-05-26 2003-02-20 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
US6166072A (en) 1998-08-03 2000-12-26 Allelix Neuroscience, Inc. Amino acid derivatives
WO2000031020A1 (fr) 1998-11-25 2000-06-02 Warner-Lambert Company Analogues d'acide gamma-aminobutyrique ameliores
AU3216600A (en) * 1999-03-10 2000-09-28 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
DE60012508T2 (de) 1999-05-26 2005-06-23 Warner-Lambert Company Llc Aminosäuren mit polycyclischer struktur als pharmaka
AU4673200A (en) 1999-05-28 2000-12-18 Warner-Lambert Company 3-heteroarylalkyl substituted gaba analogs
ES2185591T3 (es) 1999-06-02 2003-05-01 Warner Lambert Co Amino hererociclos utiles como agentes farmaceuticos.
TNSN03094A1 (fr) 2001-04-19 2005-12-23 Warner Lambert Co Amino-acides condenses bicycliques ou tricycliques
BRPI0514692A (pt) 2004-08-27 2008-06-17 Esteve Labor Dr inibidores do receptor sigma
EP1820502A1 (fr) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Combinaisons de principes actifs comprenant de dérivés d' azolylcarbinol
EP2116539A1 (fr) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles en tant que ligands améliorant les effets analgésiques des opioïdes et réduisant leur dépendance
EP2292236A1 (fr) 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention ou le traitement de douleurs induites par la chimiothérapie
US20130143884A1 (en) 2009-11-25 2013-06-06 Maria Rosa Cuberes-Altisent 4-[2-[ [5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl] morpholine salts
EP2335688A1 (fr) 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Compositions pharmaceutiques comprenant des ligands du récepteur sigma
EP2353591A1 (fr) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la potentialisation de l'effet analgésique d'opioïdes et d'opiacés dans la douleur post-opératoire et en atténuant la dépendance
WO2011095579A1 (fr) 2010-02-04 2011-08-11 Laboratorios Del Dr. Esteve, S.A. Polymorphes et solvates de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
EP2388005A1 (fr) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Ligands sigma pour la prévention et/ou le traitement du vomissement induit par la chimiothérapie ou la radiothérapie
EP2415471A1 (fr) * 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans l'hyperalgie induite par opioïdes
EP2426111A1 (fr) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. Formes cristallines de chlorhydrate de 4-[-2-[[5-méthyl-1-(2-naphtalényl)-1h-pyrazol-3-yl]oxy]éthyl]morpholine
EP2460519A1 (fr) 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma pour la douleur du cancer des os
EP2524694A1 (fr) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Utilisation de ligands sigma dans la douleur liée au diabète de type 2
EP2818166A1 (fr) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Utilisation de ligands des récepteurs sigma pour la prévention et le traitement de la douleur associée à la cystite interstitielle/au syndrome de la vessie douloureuse (IC/BPS)

Also Published As

Publication number Publication date
SG11201604478UA (en) 2016-07-28
AU2014364644A1 (en) 2016-06-23
EP3082790A1 (fr) 2016-10-26
TW201607539A (zh) 2016-03-01
MX2016007286A (es) 2016-08-04
JP2017503765A (ja) 2017-02-02
WO2015091505A1 (fr) 2015-06-25
US20160310501A1 (en) 2016-10-27
AR101637A1 (es) 2017-01-04
KR20160098426A (ko) 2016-08-18
CN105873580B (zh) 2020-08-25
IL245977A0 (en) 2016-07-31
PH12016501095A1 (en) 2016-07-11
CA2933057A1 (fr) 2015-06-25
TN2016000229A1 (en) 2017-10-06
CN105873580A (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
MA38957B1 (fr) Combinaisons d'anti-inflammatoire non stéroïdien (ains) et de ligand des récepteurs sigma
MA39147B1 (fr) Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
CR20160170A (es) Moduladores del factor del complemento b
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EA201690044A1 (ru) Модуляторы ядерного транспорта и их применение
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA47356B1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EA201792592A1 (ru) Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
EA201990424A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
EA201792591A1 (ru) Фармацевтические препараты
UA108859C2 (uk) Ліганди сигма-рецепторів для попередження або лікування болю, викликаного хіміотерапією таксанами, вінкаалкалоїдами, лікарськими засобами на основі платини і талідомідом
EA201791219A1 (ru) Антибактериальные композиции, имеющие широкий спектр активности
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
BR112015032343A2 (pt) uso de ligantes receptores sigma para a prevenção e tratamento de dor associada à cistite intersticial/síndrome da bexiga dolorosa (ic/bps)
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EA201790973A1 (ru) A-антагонист в низкой дозировке для лечения adhd и болезни паркинсона